Prevention & care

Cardiomyopathy: heart muscle phenotypes, inherited disease, assessment, recovery, and targeted treatment evidence

11 sources · Latest source check 2026-10-09 UTC

On this page

Cardiomyopathy is disease affecting the heart muscle. Changes in muscle thickness, stiffness, chamber size or tissue composition can impair filling, pumping or electrical function. The label covers several patterns and causes; it does not identify one uniform condition or mean that every affected heart has an enlarged chamber.[1]

Common patterns describe different structural or functional problems

Common patterns describe different structural or functional problems
Pattern	Broad meaning
Dilated cardiomyopathy	Enlarged, weakened ventricles with impaired pumping.[2]
Hypertrophic cardiomyopathy	Abnormally thick muscle; obstruction can occur but is not universal.[2]
Restrictive cardiomyopathy	Stiff ventricles that cannot fill normally.[2]
Arrhythmogenic cardiomyopathy	Muscle replacement by abnormal tissue, with important rhythm risk; presentations can overlap.[2]
Non-dilated left ventricular cardiomyopathy	The ESC framework also recognizes disease with nonischemic scar or other dysfunction without chamber enlargement.[6]

A muscle diagnosis and heart failure are related concepts

NHLBI describes heart failure and arrhythmias as possible consequences of cardiomyopathy. A muscle diagnosis identifies a disease pattern; heart failure concerns the resulting failure to meet the body’s circulatory needs. Several pathways can produce heart failure. A rhythm problem, thick muscle or impaired filling can matter even when a reader expects every important abnormality to be a weak, enlarged pump.[1]

Patterns can overlap, and pregnancy or acute illness changes the question

NHLBI notes overlapping cardiomyopathies and describes peripartum disease during or after pregnancy. It also discusses transient dysfunction in sepsis or severe stress. These contexts have different causes and trajectories. An expectation of recovery in one setting should not be transferred to an inherited or persistently scarred muscle condition.[2]

Different references may classify the same finding differently

NHLBI lists left ventricular noncompaction among its types. The 2023 ESC guideline instead treats prominent ventricular trabeculation as a phenotype that can occur alone or alongside another disorder, favoring the term hypertrabeculation. It similarly separates transient takotsubo syndrome from its cardiomyopathy classification. These differences concern classification; an imaging appearance still needs assessment of function, symptoms and context.[6]

Familial disease does not mean every case has a known genetic answer

MedlinePlus Genetics describes nonsyndromic dilated cardiomyopathy occurring in families, with variation in age of onset and severity. Multiple genes involved in muscle contraction or structural support can contribute. Some families have no identified causal variant. A disease label, family history and a genetic test each provide different information rather than one guaranteed prediction for every relative.[5]

Family assessment is more than buying a consumer DNA report

NHLBI’s diagnostic pathway asks about affected relatives and sudden death and may recommend assessment of family members. Genetic counseling helps explain testing and its consequences. Clinical imaging and electrical evaluation remain separate tools. Family communication and specialist interpretation are therefore part of care; a single consumer result cannot reproduce the entire diagnostic pathway.[3]

Echo, MRI and ECG answer different questions

Echocardiography assesses heart structure and function. Cardiac MRI can provide additional structural and tissue information. An ECG examines electrical activity; selected other tests address specific uncertainties. NHLBI presents these as components of a clinical work-up. The article does not reduce the diagnosis to one ejection-fraction value, a wearable rhythm notification or muscle thickness considered in isolation.[3]

Treatment follows the cause, phenotype and complications

NHLBI separates relieving symptoms, addressing the underlying cause and preventing complications. Medicines, devices or procedures may serve different purposes, and some forms improve without being permanently cured. Pregnancy and breastfeeding can change medication choices. General healthy-lifestyle care supports the person but does not make treatment identical across inherited, inflammatory and other muscle diseases.[4]

TRED-HF tested withdrawal after apparently recovered dilated cardiomyopathy

The open-label pilot randomized 51 selected patients whose symptoms, pumping function and other measurements had improved: 25 to phased treatment withdrawal and 26 to continuation. In the first six months, 11 withdrawal participants (44%) relapsed versus none continuing treatment. The relapse endpoint combined clinical and objective deterioration; it was not simply death or hospital admission.[7]

The study received charity and research-institution support. Its small, selected population limits generalization across every cardiomyopathy. It nevertheless directly challenges the assumption that feeling well and having recovered measurements make unsupervised medication withdrawal safe. The tested withdrawal pathway included monitoring and restarting treatment at relapse.[7]

Later TRED-HF follow-up is useful but is the same cohort

Follow-up of the same 51 participants found 33 (65%) had relapsed over median six years; estimated five-year relapse was 61%, with a 95% confidence interval of 45–73%. After the trial, treatment choices and intensity changed. This phase was not a continuing randomized comparison of lifelong withdrawal against continuation and is not an independent replication in a new population.[8]

Aficamten evidence applies to symptomatic obstructive HCM

The FDA approved Myqorzo (aficamten) on December 19, 2025 to improve functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy. SEQUOIA-HCM randomized 282 patients to drug or placebo. At 24 weeks, the between-group difference in change in peak oxygen uptake was 1.7 mL/kg/min, with a 95% confidence interval of 1.0–2.4.[9]

Peak oxygen uptake is an exercise-capacity endpoint, not direct proof of longer survival or prevention of every HCM complication. The trial population, obstruction and symptom requirements matter. These results cannot be generalized to nonobstructive HCM, dilated cardiomyopathy or enhancement in healthy athletes.[9]

A targeted drug still has important restrictions

The US label identifies aficamten as a cardiac myosin inhibitor and warns of systolic dysfunction and heart failure. Echocardiographic assessment before and during treatment, restricted REMS distribution and drug-interaction precautions form part of its use. Approval is therefore not permission to experiment with reducing heart-muscle contraction without specialist assessment. Eligibility and monitoring are product-specific.[10]

The linked 2026 correction matters when reading the older guideline

An August 17, 2026 notice corrects childhood HCM incidence/prevalence decimal errors and changes the iron-status MRI entry from increased to decreased T2* values. The original version of record is retained, so an older table alone may still contain the error. This is a specific correction, not a new diagnostic shortcut or an independent treatment-effect study.[11]

Evidence & uncertainty

Important treatments and diagnostic frameworks exist, but recovery is not always cure. TRED-HF found relapse after treatment withdrawal in selected recovered dilated cardiomyopathy. New drug evidence also has narrow eligibility: the aficamten approval concerns symptomatic obstructive hypertrophic cardiomyopathy, not all heart muscle disease.[7][9]

Selected-source overview · Independent review pending

Published questions

Does cardiomyopathy always mean an enlarged weak ventricle?

Selected-source overview · Independent review pending. Read the evidence context.

Thick, stiff, arrhythmogenic and non-dilated patterns also occur.[2][6]

Evidence behind this answer

Cardiomyopathy: types
agency condition or prevention explanation · 2024
Selected relevant original official page passages inspected · December 2024: DCM, HCM, restrictive/arrhythmogenic patterns and pregnancy/acute-illness contexts
2023 ESC Guidelines for the management of cardiomyopathies
professional guidance · 2023
Original indexed selected guideline passages and official scope summary inspected · Non-dilated LV phenotype and section 3.3 classification of hypertrabeculation/takotsubo